Lymphotoxin-Beta Receptor Blockade Reduces CXCL13 in Lacrimal Glands and Improves Corneal Integrity in the NOD Model of Sjögren's Syndrome
Roy A Fava;Susan M Kennedy;Sheryl G Wood;Anne I Bolstad;Jadwiga Bienkowska;Adrian Papandile;John A Kelly;Clio P Mavragani;Margaret Gatumu;Kathrine Skarstein;Jeffrey L Browning
Abstract
IntroductionIn Sjögren's syndrome, keratoconjunctivitis sicca (dry eye) is associated with infiltration of lacrimal glands by leukocytes and consequent losses of tear-fluid production and the integrity of the ocular surface. We investigated the effect of blockade of the lymphotoxin-beta receptor (LTBR) pathway on lacrimal-gland pathology in the NOD mouse model of Sjögren's syndrome.MethodsMale NOD mice were treated for up to ten weeks with an antagonist, LTBR-Ig, or control mouse antibody MOPC
This paper has been withdrawn.